Profitability Metrics

Gross Margin
19.83%
Operating Margin
99.61%
Net Margin
99.61%

Efficiency Metrics

Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
99.61%
Income Tax Rate
0.00%
EPS
3.4500000000

Balance Sheet Analysis

Current Ratio
0.03
Cash Ratio
0.67
Working Capital
$-19.29M
Debt to Equity
0.00
Debt to Assets
0.00%
Equity Ratio
97.77%

Cash Flow Analysis

Operating Cash Flow Ratio
-7.11%
Free Cash Flow Ratio
-7.11%
CapEx to Revenue
0.00%
Dividends Paid
$54.52M
Stock Buybacks
No buybacks
Total Shareholder Returns
$54.52M
Cash Position Change
-133,016,600.0%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
241.99%
Net Income
240.78%
EPS
240.82%
Operating Income
240.77%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
-1.11%
Operating Cash Flow
-39.55%
Free Cash Flow
-39.55%

Balance Sheet Health

Assets
13.87%
Debt
-100.00%
Book Value per Share
12.84%
Inventory
0.00%

Shareholder Returns

Dividends per Share
-39.84%
Shares Outstanding
0.03%

Long Term Trends

3Y Revenue/Share
55.67%
5Y Revenue/Share
480.60%
3Y Dividend/Share
17.68%
5Y Dividend/Share
23.91%